Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Clinical trial NCT04070040 · RECRUITING
Trial details
- NCT number
- NCT04070040
- Sponsor
- Beijing Sanbo Brain Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-13
- Primary completion
- 2024-12-31
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.